Clinical Analysis Of Postoperative Serum CA125 In Serous Ovarian Carcinoma

Objective : To investigate the relation between the change of postoperative serum carbohydrate antigen 125(CA125)and the recurrence time in patients with stage Ⅲ serous ovarian carcinoma and to observe the serum CA125 at recurrence.To further discuss about the significance of monitoring the change of postoperative serum CA125 in order to estimate the serous ovarian carcinoma patients’ progression of disease.Methods:Patients with stage Ⅲ serous ovarian carcinoma who were first diagnosed and treated with standard treatment from January 2012 to January 2019 in the first affiliated hospital of Chongqing Medical University are selected,whose complete clinical data,postoperative pathological data and postoperative serum CA125 values are collected,and the recurrence is recorded during follow-up.According to the number of chemotherapy courses required for the conversion of serum CA125 value to negative(CA125 < 35 U/mL was negative)during the postoperative treatment,the patients are divided into two groups,and then the patients are divided into two groups according to the difference of the lowest value of serum CA125 during the postoperative treatment.Statistical software isused to compare the discrepancy between different groups’ recurrence time,as well as the discrepancy between different groups’ serum CA125 at recurrence.Results:There are 36 recurrence cases in 48 patients with stage Ⅲ serous ovarian carcinoma during follow-up.The recurrence time of the group that the number of chemotherapy courses required for the conversion of serum CA125 value to negative is more than or equal to 3 is shorter than that of another group,and there is a significant difference(P<0.05).The recurrence time of the group with the lowest value of serum CA125 more than 10 U/mL is shorter than that of another group,and there is also a significant difference(P<0.05).Meanwhile,the serum CA125 value at recurrence of the group that the number of chemotherapy courses required for the conversion of serum CA125 value to negative is more than or equal to 3 is higher,and the difference between the two groups is significant(P<0.05).Although the serum CA125 at recurrence of the group with the lowest value of serum CA125 more than 10 U/mL is higher,the difference between the two groups is not significant(P>0.05).Of the 36 recurrence cases,7 cases’ serum CA125 value at recurrence are less than 35 U/mL,that of which the number of chemotherapy courses required for the conversion of serum CA125 value to negative is no more than three.Among 7 recurrence cases,the lowest value of serum CA125 less than or equal to 10 U/mL during the postoperative treatment are 4 cases,whichhave the lower serum CA125 at recurrence,however,there is no significant difference between the two groups(P>0.05).Conclusion:During the decrease of postoperative serum CA125 value in 48 patients with stage Ⅲ serous ovarian cancer,if the patients can turn negative in three chemotherapy cycles,the recurrence time is later and the progress of the disease is slower.Similarly,if the lowest serum CA125 value is less than or equal to 10 U/mL after it turns negative,the recurrence time is later and the progress of the disease is slower.For stage Ⅲ serous ovarian carcinoma patients,it is necessary to closely monitor the changes of serum CA125 after operation,which can have a certain judgment on the progress of the disease.